Clinical Outcomes of Percutaneous Mitral Valve Repair with Mitraclip: A Longitudinal Observational Study (The Mitra-Angio-CDO Study)

Luis Álvaro Melo-Burbano,1– 3 Diana Marcela Bonilla-Bonilla,1– 3 Jorge Enrique Daza-Arana,1,4 Heiler Lozada-Ramos,1,3– 5 Antonio Enrique Dager,6 Jaime Andrés Fonseca6 1School of Health, Internal Medicine Specialization Program, Universidad Santiago de Cali, Santiago de Cali, Valle del Cauca, Colombia; 2Research and Education Department, Clínica de Occidente S.A., Santiago de Cali, Valle del Cauca, Colombia; 3Genetics, Physiology, and Metabolism Research Group (GEFIME), Universidad Santiago de Cali, Santiago de Cali, Valle del Cauca, Colombia; 4Health and Movement Research Group, Universidad Santiago de Cali, Santiago de Cali, Valle del Cauca, Colombia; 5Doctorate Degree Program in Infectious Diseases, Universidad de Santander, Bucaramanga, Santander, Colombia; 6Angiografía de Occidente S.A., Santiago de Cali, Valle del Cauca, ColombiaCorrespondence: Jorge Enrique Daza-Arana, Universidad Santiago de Cali, Calle 5 6200, Pampalinda, Cali, Valle del Cauca, 760043, Colombia, Tel +57 3108923676, Email jorge.daza01@usc.edu.co; jorgedaza.epidemiologia@gmail.comBackground: The MitraClip device is used as an endovascular therapy for mitral valve repair in patients with severe mitral insufficiency and high surgical risk. This therapy was used for the first time in Colombia in 2013, after its authorization by the National Institute of Drug and Food Surveillance.Materials and Methods: A quantitative, observational, descriptive, longitudinal study was conducted, with an analytical component stratified by age, in adults who underwent mitral valve repair with MitraClip from March 2013 to June 2022 to determine the clinical outcomes associated with hospitalization, mortality, complications, and health-related quality of life.Results: A total of 94 patients with a mean age of 70.3± 10.3 years were evaluated, most of whom were male (65%), hypertensive (80%), and had New York Heart Association class III–IV classification (90.4%) and functional mitral insufficiency (93.6%) classified as severe (74.5%). The recurrence of all-cause hospitalization was 39.4%, of which 88% corresponded to heart failure. The immediate success of the procedure, determined as mitral insufficiency classified as ≤moderate after implantation, was 93.6% (p 70 years 13.7%, p = 0.007), mortality at 1 year was 16%, and mortality at 2 years was 20.2%. The incidence of complications was low, the most frequent one being de novo atrial fibrillation (7.4%), followed by major bleeding requiring transfusion (4.3%). The Kansas City Cardiomyopathy Questionnaire scale was used, with a mean score of 69.9± 19.3.Conclusion: Percutaneous mitral valve repair with MitraClip is a safe technique that directly affects survival and quality of life. There was a low incidence of complications related to the procedure and the patient’s preoperative condition, with results comparable to those of studies carried out in Europe and the United States.Keywords: heart failure, severe mitral insufficiency, percutaneous mitral valve repair, survival, quality of life. (source: MeSH)